Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers
NCT06537960 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66
Last updated 2025-11-21
Summary
The goal of this study is to demonstrate a significant gain in sensitivity versus surgical curage (extended pelvic) for initial lymph node staging of late FDG-PET images (2.5 hours) versus standard images (1 hour), analyzed by side (right iliac/left iliac areas in Patients with muscle-invasive bladder tumor (MIBT) (≥pT2) referred for FDG-PET in the nuclear medicine department of Hôpital Foch as part of their initial extension workup.
Before performing 18FDG PET-CT, the operator checks that the patient has fasted for at least 6 hours and that blood glucose levels are below 11 mmol/l. In the absence of contraindication, intravenous (IV) injection of the radiopharmaceutical (18FDG at a dose of 3 MBq/kg) and a diuretic (Furosemide 20mg) will be performed as part of routine care. The 18FDG PET-CT scan will be performed in 2 phases:
1st phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer. PET acquisition is coupled to a "base-dose" CT scan in spontaneous contrast, for anatomical location, measurement of lymph node size, and creation of an attenuation map, necessary for correction of attenuation and diffusion on PET images (DLP estimated at around 500 mGy.cm on average). Micturition is performed as part of routine care just before the first acquisition.
Phase 2: Complementary abdomino-pelvic acquisition at 2.5 hours post-injection (2 or 3 steps depending on patient size. This second PET acquisition is coupled to an "ultra-base-dose" CT scan in spontaneous contrast, to be used only for attenuation and diffusion correction (DLP estimated at around 100 mGy.cm on average). Micturition is performed 30 minutes before the second acquisition.
The patient's proposed therapeutic management will be decided at the PCR once the extension work-up has been carried out, as part of routine care. For this purpose, only "standard" 18FDG PET-CT images may be used.
As a general rule, patients with distant metastases (stage pT2N+M+) will receive palliative treatment, while surgical treatment from the outset, or after chemotherapy for patients with stage pT2N0M0 or pT2N+M0, will be discussed on a case-by-case basis at the multidisciplinary consultation meeting.
Late" images will be used after lymph node curage, in patients who have not had chemotherapy prior to surgery (cystectomy + extended pelvic lymph node curage), to determine the sensitivity of these complementary images.
Conditions
- Muscle-Invasive Bladder Carcinoma
- Bladder Cancer
Interventions
- PROCEDURE
-
18FDG PET-CT
18FDG PET-CT will be performed in 2 phases: 1. st standard phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer 2. nd phase: Complementary abdomino-pelvic acquisition at 2.5 hours post radiotracer injection.
Sponsors & Collaborators
-
Hopital Foch
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-14
- Primary Completion
- 2027-03-15
- Completion
- 2027-03-15
Countries
- France
Study Locations
More Related Trials
-
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
NCT03327883 ·Status: COMPLETED
-
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
NCT05531045 ·Status: NOT_YET_RECRUITING
-
Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
NCT00915096 ·Status: COMPLETED
-
Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer
NCT04008095 ·Status: COMPLETED
-
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
NCT06349512 ·Status: RECRUITING ·Phase: NA
-
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
NCT00534989 ·Status: COMPLETED ·Phase: NA
-
PET/MRI and Biomarkers in Bladder Cancer
NCT01918592 ·Status: COMPLETED ·Phase: NA
-
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
NCT02317393 ·Status: COMPLETED ·Phase: PHASE2
-
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
NCT06548529 ·Status: RECRUITING ·Phase: NA
-
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
NCT05486182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
NCT05983796 ·Status: UNKNOWN ·Phase: NA
-
Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
NCT00904410 ·Status: COMPLETED ·Phase: PHASE4
-
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
NCT06852807 ·Status: RECRUITING
-
Benefits Study of Respiratory-gated PET Acquisition in Lung Disease
NCT01812031 ·Status: COMPLETED ·Phase: NA
-
PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.
NCT00741481 ·Status: COMPLETED
-
11C-Acetate PET/CT Non-FDG-Avid Tumors
NCT00687778 ·Status: UNKNOWN
-
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
NCT05392205 ·Status: COMPLETED ·Phase: NA
-
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
NCT05396118 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma
NCT02931201 ·Status: UNKNOWN ·Phase: NA
-
Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival
NCT01261598 ·Status: COMPLETED ·Phase: NA
-
Benefits Study of Respiratory-gated Positron Emission Tomography Acquisitions of the Liver
NCT01219985 ·Status: COMPLETED ·Phase: NA
-
SUV on PSMA PET/CT in Non-Prostate Tumors
NCT03841760 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging
NCT02792959 ·Status: COMPLETED ·Phase: NA
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
NCT06597539 ·Status: RECRUITING
-
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592 ·Status: TERMINATED ·Phase: PHASE1